Akorn, Inc. is recalling 58,393 jars of Clindamycin Phosphate Topical Solution USP, 1% (10 mg/mL), which is a prescription medication used to treat acne. The recall was initiated because testing showed the product failed to meet specifications for impurities and degradation, meaning the chemical composition of the medicine changed over time. Approximately 58,393 jars across ten specific lot numbers are affected by this nationwide recall. If you have this medication, you should contact your doctor or pharmacist to discuss your treatment and learn how to obtain a refund.
The product has observed 'out of specification' results for impurities and degradation, which means the medication may not maintain its required strength or quality through its expiration date. While this recall is classified as low risk, using a degraded medication may result in reduced effectiveness for treating your condition.
Drug recall return and refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.